Openbookopenbook
Equity
Zymeworks Inc. Common Stock(ZYME)
USD --+0.00%
Reward51Moderate
Risk54Moderate
📊75%Data
Thin -47% profit margin · Revenue growing 73% YoY
ZYME
+0.0 · +0.00%
USD · NASDAQ
Zymeworks Inc. Common Stock | Healthcare
Profitless Growth
Market Cap:1.77Bn
ℹ️
Reward Rating
51
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
54
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ZYME to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $36.46.

What is Zymeworks Inc. Common Stock?

, a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID).

ZYME · Verdict

Moderate reward · elevated risk

ZYME's standout is balance sheet; cash flow and profitability weigh on the picture.

Based on 88% data coverage

ZYME · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet86/100

    Current ratio 3.40

Watchouts 3

  • Cash flow6/100

    -148% free-cash-flow margin

  • Profitability32/100

    -161% net margin · -18% ROE

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Zymeworks Inc. Common Stock?

, a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.77B.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (51)

The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.77B
P/E RatioN/A
Dividend YieldN/A
52 Week High28.49
52 Week Low9.03
Last AnnualDecember
IPO Date4/28/2017
IncorporatedUSA
Shares Outstanding75M
No. of Employees263
IndustryBiotechnology
ExchangeNASDAQ
Beta1.237
CurrencyUSD
Websitewww.zymeworks.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.